e-6201
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00539929)
Timeline
Indications
Mechanism of action
MAP3K1 inhibitor
MAP2K1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCNc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\[C@@H](C)[C@H](C)OC2=O- Mol. weight
- 389.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1097999 ↗
Also known as
- 14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1h-2-benzoxacyclotetradecine-1,7(8h)-dione
- e6201
- e6201
- e 6201
- e-6201
- e-6201
- e-6201
- e-6201
- e6201 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05388877 | Phase 1 | Sep 30, 2022 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03332589 | Phase 1 | Jul 2, 2018 | Strategia Therapeutics, University of Arizona |
| NCT02418000 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Strategia Therapeutics, University of Texas at Houston |
| NCT01268527 | Phase 2 | Mar 1, 2010 | Eisai |
| NCT00794781 | Phase 1 | Jun 1, 2008 | Eisai |
| NCT00539929 | Phase 2 | Sep 1, 2007 | Eisai |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 3 | 3 | 2 | 2007 |
| Strategia Therapeutics | For profit | 2 | 2 | 2 | 2015 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2015 |
6 organizations
Page 1 / 1